Valuation: Roche Holding AG

Market Cap 27TCr 33TCr 29TCr 25TCr 47TCr 31,59200Cr 48TCr 3,21200Cr 1,24800Cr 15,46000Cr 1,23900Cr 1,21200Cr 53,66700Cr P/E 2026 *
17.8x
P/E 2027 * 16.7x
Enterprise Value 28TCr 34TCr 30TCr 26TCr 49TCr 32,84100Cr 50TCr 3,33900Cr 1,29700Cr 16,07100Cr 1,28800Cr 1,26000Cr 55,78900Cr EV / Sales 2026 *
4.43x
EV / Sales 2027 * 4.16x
Free-Float
88.78%
Yield 2026 *
2.99%
Yield 2027 * 3.06%
Current month+0.48%
6 months-4.79%
Current year-1.29%
Current year 311.6
Extreme 311.6
377
1 year 221.3
Extreme 221.3
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 34TCr
-1.60%+2.02%+56.34%+168.94% 1,10200Cr
-1.44%+3.71%+69.07%+65.40% 64TCr
-0.75%+0.67%+33.18%+86.52% 45TCr
-0.86%+2.79%+37.72%+40.85% 30TCr
-0.71%+0.72%+28.85%+48.27% 29TCr
-1.31%-0.26%-28.18%-39.82% 22TCr
-0.03%+1.84%+23.90%+68.30% 20TCr
-0.40%+7.82%+22.29%+82.50% 17TCr
-0.08%+0.71%-6.13%-32.31% 14TCr
Average -0.72%+2.81%+26.34%+54.30% 38.97TCr
Weighted average by Cap. -1.00%+2.70%+40.61%+87.66%

Financials

2026 *2027 *
Net sales 6.26TCr 7.73TCr 6.78TCr 5.79TCr 11TCr 7,40600Cr 11TCr 75TCr 29TCr 3,62400Cr 29TCr 28TCr 12,58100Cr 6.52TCr 8.05TCr 7.06TCr 6.03TCr 11TCr 7,71000Cr 12TCr 78TCr 30TCr 3,77300Cr 30TCr 30TCr 13,09700Cr
Net income 1.52TCr 1.88TCr 1.65TCr 1.41TCr 2.67TCr 1,80300Cr 2.72TCr 18TCr 7.12TCr 88TCr 7.07TCr 6.92TCr 3,06300Cr 1.63TCr 2.01TCr 1.76TCr 1.51TCr 2.85TCr 1,92600Cr 2.91TCr 20TCr 7.61TCr 94TCr 7.55TCr 7.39TCr 3,27200Cr
Net Debt 1.06TCr 1.3TCr 1.14TCr 976.19Cr 1.85TCr 1,24900Cr 1.89TCr 13TCr 4.93TCr 61TCr 4.9TCr 4.79TCr 2,12200Cr 386.64Cr 477.47Cr 418.79Cr 357.29Cr 677.2Cr 46TCr 690.76Cr 4.65TCr 1.81TCr 22TCr 1.79TCr 1.75TCr 78TCr
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
1,03,249
Date Price Change Volume
08/26/08 CHF 323.90 0.00% 6,493
07/26/07 CHF 323.90 0.00% 1,400
06/26/06 CHF 323.90 0.00% 2,786
03/26/03 CHF 323.90 0.00% 496
02/26/02 CHF 323.90 0.00% 2,593
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
334.90CHF
Average target price
359.22CHF
Spread / Average Target
+7.26%

Quarterly revenue - Rate of surprise